19 October 2026
19 October 2026
The capital will fund clinical proof-of-concept testing for Estuary's lead gene therapy candidates, EST-101 and EST-201.
The liquid biopsy is intended for use alongside regular screening to detect cellular and molecular markers of early-stage disease.
The trial took place across 14 clinical locations in the US and included 151 participants.
MINItrace Magni is an automated, self-shielded cyclotron developed for in-house radioisotope manufacturing.
The studies enrolled around 1800 participants to test the drug's safety and efficacy in preventing both chronic and episodic migraine.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
